Cargando…

Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study

OBJECTIVES: This analysis from the PERSPECTIVE (a Prospective, Non‐interventional Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder) study evaluated treatment persistence with mirabegron or antimuscarinics over a 12‐month period. METHODS: Participants were adults...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlson, Kevin V., Rovner, Eric S., Nair, Kavita V., Deal, Anna S., Kristy, Rita M., Hairston, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Asia Pty Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518921/
https://www.ncbi.nlm.nih.gov/pubmed/33987973
http://dx.doi.org/10.1111/luts.12382
_version_ 1784584340179517440
author Carlson, Kevin V.
Rovner, Eric S.
Nair, Kavita V.
Deal, Anna S.
Kristy, Rita M.
Hairston, John C.
author_facet Carlson, Kevin V.
Rovner, Eric S.
Nair, Kavita V.
Deal, Anna S.
Kristy, Rita M.
Hairston, John C.
author_sort Carlson, Kevin V.
collection PubMed
description OBJECTIVES: This analysis from the PERSPECTIVE (a Prospective, Non‐interventional Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder) study evaluated treatment persistence with mirabegron or antimuscarinics over a 12‐month period. METHODS: Participants were adults diagnosed with overactive bladder (OAB) by their health care provider (HCP), who were initiating mirabegron or antimuscarinic treatment. The HCP made all treatment decisions, and patients were followed for 12 months with no mandatory scheduled visits. Information requests were sent to patients at baseline and months 1, 3, 6, and 12. Patients were nonpersistent if they switched, discontinued, or added OAB medications/therapies to their initial treatment. Reasons for discontinuation and switching patterns were investigated. RESULTS: Overall, 1514 patients were included (613 mirabegron and 901 antimuscarinic initiators). Persistence rates decreased steadily over time in both groups. A low proportion of patients added or switched medication at each time point. Unadjusted Kaplan‐Meier analysis showed similar persistence rates for both groups. When the data were adjusted for patient characteristics (age, sex, and OAB treatment status), mirabegron initiators had higher persistence rates. No significant differences were noted in unadjusted median time to end of persistence. However, end of treatment persistence by any cause was longer with mirabegron (median: 9.5 vs 6.7 months for antimuscarinics). HCPs stated that the most common reasons for nonpersistence were no symptomatic improvement and side effect aversion. CONCLUSIONS: Treatment persistence was longer for mirabegron compared with antimuscarinic initiators after controlling for patient characteristics. End of treatment persistence by any cause was also longer with mirabegron.
format Online
Article
Text
id pubmed-8518921
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Blackwell Publishing Asia Pty Ltd
record_format MEDLINE/PubMed
spelling pubmed-85189212021-10-21 Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study Carlson, Kevin V. Rovner, Eric S. Nair, Kavita V. Deal, Anna S. Kristy, Rita M. Hairston, John C. Low Urin Tract Symptoms Original Articles ‐ Clinical OBJECTIVES: This analysis from the PERSPECTIVE (a Prospective, Non‐interventional Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder) study evaluated treatment persistence with mirabegron or antimuscarinics over a 12‐month period. METHODS: Participants were adults diagnosed with overactive bladder (OAB) by their health care provider (HCP), who were initiating mirabegron or antimuscarinic treatment. The HCP made all treatment decisions, and patients were followed for 12 months with no mandatory scheduled visits. Information requests were sent to patients at baseline and months 1, 3, 6, and 12. Patients were nonpersistent if they switched, discontinued, or added OAB medications/therapies to their initial treatment. Reasons for discontinuation and switching patterns were investigated. RESULTS: Overall, 1514 patients were included (613 mirabegron and 901 antimuscarinic initiators). Persistence rates decreased steadily over time in both groups. A low proportion of patients added or switched medication at each time point. Unadjusted Kaplan‐Meier analysis showed similar persistence rates for both groups. When the data were adjusted for patient characteristics (age, sex, and OAB treatment status), mirabegron initiators had higher persistence rates. No significant differences were noted in unadjusted median time to end of persistence. However, end of treatment persistence by any cause was longer with mirabegron (median: 9.5 vs 6.7 months for antimuscarinics). HCPs stated that the most common reasons for nonpersistence were no symptomatic improvement and side effect aversion. CONCLUSIONS: Treatment persistence was longer for mirabegron compared with antimuscarinic initiators after controlling for patient characteristics. End of treatment persistence by any cause was also longer with mirabegron. Blackwell Publishing Asia Pty Ltd 2021-05-14 2021-10 /pmc/articles/PMC8518921/ /pubmed/33987973 http://dx.doi.org/10.1111/luts.12382 Text en © 2021 The Authors. LUTS: Lower Urinary Tract Symptoms published by John Wiley & Sons Australia, Ltd https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles ‐ Clinical
Carlson, Kevin V.
Rovner, Eric S.
Nair, Kavita V.
Deal, Anna S.
Kristy, Rita M.
Hairston, John C.
Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
title Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
title_full Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
title_fullStr Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
title_full_unstemmed Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
title_short Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
title_sort persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: findings from the perspective registry study
topic Original Articles ‐ Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518921/
https://www.ncbi.nlm.nih.gov/pubmed/33987973
http://dx.doi.org/10.1111/luts.12382
work_keys_str_mv AT carlsonkevinv persistencewithmirabegronorantimuscarinictreatmentforoveractivebladdersyndromefindingsfromtheperspectiveregistrystudy
AT rovnererics persistencewithmirabegronorantimuscarinictreatmentforoveractivebladdersyndromefindingsfromtheperspectiveregistrystudy
AT nairkavitav persistencewithmirabegronorantimuscarinictreatmentforoveractivebladdersyndromefindingsfromtheperspectiveregistrystudy
AT dealannas persistencewithmirabegronorantimuscarinictreatmentforoveractivebladdersyndromefindingsfromtheperspectiveregistrystudy
AT kristyritam persistencewithmirabegronorantimuscarinictreatmentforoveractivebladdersyndromefindingsfromtheperspectiveregistrystudy
AT hairstonjohnc persistencewithmirabegronorantimuscarinictreatmentforoveractivebladdersyndromefindingsfromtheperspectiveregistrystudy